Commercial Opportunities for Pulmonary Diagnosis (COPD)

“创新英国”已经向剑桥郡斯威弗西的剑桥呼吸创新有限公司授予了一项可行性研究补助金。目前，临床医生需要使用一系列医疗设备，从峰值流量计到肺活量计和脉搏血氧仪，再到扫描和x射线，来诊断呼吸系统疾病。诊断哮喘、慢性阻塞性肺病和其他慢性呼吸系统疾病最常用的设备是肺活量计和峰值流量计。这两种设备对患者来说都很难使用，依赖于用力呼气操作，依赖于技术和测量呼吸代理。呼吸窘迫的成年人和儿童不能使用这些设备。剑桥呼吸创新有限公司（CRiL）开发了一种创新的外延生长III-V型led二氧化碳传感器，该传感器比任何现有的白炽灯或荧光灯二氧化碳传感器更快、更准确、更一致。它不受呼吸中的冷凝影响，而且是成本的一小部分。CRiL开发了一种专门用于测量正常潮汐呼吸中二氧化碳波形形状的仪器，用于低成本的个人呼吸监测仪。潮汐呼吸CO2 （TBCO2）波形形状分析是一种已建立但未充分利用的呼吸条件生物标志物。虽然测量呼出二氧化碳的医疗设备（测二氧化碳计）在手术室里很常见，但测量潮汐呼吸二氧化碳的设备目前还没有用于任何形式的呼吸诊断。该项目侧重于N-Tidal诊断概念需要解决的研究、开发和采用问题，以及在初级和二级医疗社区成功商业化的可能性。该项目的目标是阐明该概念的价值主张，以帮助医疗保健提供者和其他客户了解N-Tidal诊断设备的吸引力。这包括确定：*患者和最终用户需求*患者途径所需的更改*委托和采购选项*卫生经济学*采用驱动因素。研究的主要重点领域将是用户需求、价值主张、卫生经济学和成功商业化所需的临床证据。这项研究的主要产出将是一个经过验证的、成本充分的开发计划。这项商业化可行性研究将确定是否存在任何商业、经济或证据障碍，阻碍采用基于潮汐呼吸二氧化碳测量的N-Tidal呼吸诊断设备。”

"Innovate UK has awarded a feasibility research grant to Cambridge Respiratory Innovations Limited, of Swavesey, Cambridgeshire.Currently a clinician needs to use a range of medical devices, from peak-flow meters through spirometers and pulse oximeters to scans and x-rays, to diagnose a respiratory condition. The most commonly used devices to diagnose asthma, COPD and other chronic respiratory diseases are spirometers and peak-flow meters. Both devices are difficult for patients to use, rely on forced expiratory manoeuvres, are technique dependent and measure a respiratory proxy. Adults in respiratory distress and children cannot use these devices.Cambridge Respiratory Innovations Limited (CRiL) has developed an innovative epitaxially-grown III-V LED-based CO2 sensor which is faster, more accurate and more consistent than any existing incandescent or florescent CO2 sensor. It is not affected by condensation in the breath and is a fraction of the cost. CRiL has developed it specifically to measure the CO2 waveform shape in normal tidal breathing to use in low-cost personal respiratory monitors. Tidal breathing CO2 (TBCO2) waveform shape analysis is an established but under-used biomarker for respiratory conditions. Whilst medical devices that measure exhaled CO2 (capnometers) are commonplace in the operating theatre, devices that measure tidal breathing CO2 are not used in any form of respiratory diagnosis at the moment.This project focuses on the research, development and adoption issues that the N-Tidal diagnostic concept will need to address and the likelihood of success in commercialisation in the primary and secondary care medical communities. The objectives of this project are to clarify the value proposition of the concept to help healthcare providers and other customers to understand the attractiveness of the N-Tidal diagnostic device. This includes determining:* patient and end user needs* the required changes to patient pathways* commissioning and procurement options* health economics* adoption driversThe main areas of focus of the research will be the users' needs, the value proposition, the health economics and the clinical evidence required for successful commercialisation. The primary output from this study will be a validated and fully-costed development plan. This commercialisation feasibility study will identify whether there are any commercial, economic or evidence impediments which hinder the adoption of the N-Tidal respiratory diagnostic device based on tidal breathing CO2 measurement."